Influenza VirusesELREVINCT07813481
ELderly REspiratory VIral Cohort
An observational study of Influenza Viruses and Respiratory Syncytial Virus (RSV), run by Assistance Publique - Hôpitaux de Paris.
Trial summary
In addition to SarsCov2, the main viral respiratory risks are associated with influenza viruses, respiratory syncytial virus (RSV), human metapneumovirus (hMPV) parainfluenza virus (PIV), adenovirus, rhinovirus, coronavirus and others. HMPV is a respiratory virus discovered in 2001. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Influenza Viruses, Respiratory Syncytial Virus (RSV), Severe Acute Respiratory Syndrome Coronavirus 2
- What is being tested?
- Respiratory viral infection
- How many people
- 1,000 participants
- Where
- No sites listed yet
- Study dates
- Oct 2026to Oct 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: Patients aged >65 years with a diagnosis of acute respiratory infection and hospitalized in acute/geriatric wards
Who may be able to join
- Patient aged 65 years or older
- Positive PCR from a nasopharyngeal swab for a respiratory viral pathogen as listed: Influenza A and B, SarsCov2, RSV, hMPV, Rhinovirus/Enterovirus, Adenovirus, Coronavirus (229E, HKU1, NL63, OC43), Parainfluenza Virus 1, 2, 3, 4.
- Hospitalized in an Acute Medicine/Geriatrics Unit
- Written informed consent from patient or his/her representative, with trusted support person, a family member or, failing that, a close friend if the person is physically unable to give his or her written consent. Patients under legal protection (guardianship, curatorship, family authorisation or future protection mandate) may be included with the consent of the legally authorised person.
- Affiliated to a social security scheme
Who cannot join
- Refusal to participate
- Patient deprived of liberty by a judicial or administrative decision
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Prognostic Role of the Human Metapneumovirus (hMPV) Compared to Other Common Respiratory Viruses in Older Inpatients: a Cohort Study
In addition to SarsCov2, the main viral respiratory risks are associated with influenza viruses, respiratory syncytial virus (RSV), human metapneumovirus (hMPV) parainfluenza virus (PIV), adenovirus, rhinovirus, coronavirus and others. HMPV is a respiratory virus discovered in 2001. Like RSV, it appears to be a threat in terms of morbidity and mortality in susceptible populations.
Overall, viral infections can cause significant functional decline in older patients, with 67% and 25% reported to be at least temporarily housebound or bedridden, respectively. Respiratory viral infections prevent older patients from functioning and performing their daily tasks. They therefore have a significant impact on the older patients and their families. In addition, respiratory viruses are key factors in the exacerbation of chronic diseases.
The aims of this study are to provide a better understanding of the role of hMPV compared to common respiratory viruses on morbimortality, risk of dependency, quality of life alteration in older inpatients.
- Conditions
- Influenza Viruses, Respiratory Syncytial Virus (RSV), Severe Acute Respiratory Syndrome Coronavirus 2, Human Metapneumovirus (hMPV), Parainfluenza Virus (PIV), Adenovirus
- Being tested
- Respiratory viral infection
- Keywords
- hMPV, RSV, PIV, SarsCov2, respiratory viruses, older adults, prognosis, morbidity, mortality
- Medical subject headings
- Adenoviridae Infections, Coronavirus Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Respiratory viral infectionOther
Respiratory viral infection identified by a positive nasopharyngeal PCR test. The prognostic role of human metapneumovirus (hMPV) infection will be compared with that of other common respiratory viral infections in older hospitalized patients.
| Study group | Role | What they receive |
|---|---|---|
| Older patients with respiratory viral infection | Patients aged 65 years or older hospitalized in acute medicine or geriatric wards with an acute respiratory infection and a positive nasopharyngeal PCR test for a respiratory viral pathogen. Receives: Other: Respiratory viral infection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of participants with death and/or organ decompensation at Day 180
Proportion of participants who died and/or experienced at least one major comorbidity decompensation (cardiac, renal, or respiratory) by Day 180.
Measured: From baseline Day 0 to Day 180
Secondary outcomes (10)
Proportion of participants who died
Proportion of participants who died from any cause during follow-up.
Measured: From baseline Day 0 to Day 30, Day 180, Day 365
Proportion of participants with major organ decompensation
Proportion of participants experiencing major decompensation of pre-existing comorbidities, including cardiac, renal, or respiratory decompensation.
Measured: From baseline Day 0 to Day 30, Day 180, Day 365
Proportion of participants with unplanned hospital readmission
Proportion of participants experiencing an unplanned hospital readmission during follow-up.
Measured: From baseline Day 0 to Day 30, Day 180, Day 365
Proportion of participants developing a lower respiratory tract infection
Proportion of participants developing a lower respiratory tract infection (LRTI) following the respiratory viral infection.
Measured: From baseline Day 0 to Day 30
Change from baseline in functional dependency assessed by ADL and/or iADL scores
Change in functional dependency from baseline, assessed using the Activities of Daily Living (ADL) and/or Instrumental Activities of Daily Living (iADL) scores.
Measured: Baseline Day 0, Day 30, Day 180, Day 365
Change from baseline in sarcopenia risk assessed by SARC-F score
Change in sarcopenia risk from baseline, assessed using the SARC-F score.
Measured: Baseline Day 0, Day 30, Day 180, Day 365
Change from baseline in quality of life assessed by EQ-5D-3L
Change in health-related quality of life from baseline, assessed using the EQ-5D-3L questionnaire.
Measured: Baseline Day 0, Day 30, Day 180, Day 365
Number and type of bacterial and viral co-infections
Number and type of bacterial and viral co-infections diagnosed at the same time as, or within seven days following, the occurrence of the first respiratory viral infection.
Measured: Baseline Day 0 to D7
Change in respiratory viral load between Day 0 and Day 7
Change in viral load between Day 0 and Day 7 for each respiratory virus identified in study participants.
Measured: From Day 0 to Day 7
Proportion of participants with death and/or major organ decompensation at Day 30
Proportion of participants who died and/or experienced major organ decompensation by Day 30. This outcome will be used to assess vaccine effectiveness for vaccine-preventable respiratory viral infections.
Measured: From baseline Day 0 to Day 30
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Sep 2026
- Study startOct 2026 (estimated)
- Primary completionApr 2030 (estimated)
- Study completionOct 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Influenza VirusesStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07813481
- Sponsor's protocol ID
- APHP250510
- Other IDs
- 2025-A02004-45
- Acronym
- ELREVI
- Status last verified
- Sep 2026
- First submitted
- 4 Sep 2026
- Last updated
- 10 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prognostic Role of the Human Metapneumovirus (hMPV) Compared to Other Common Respiratory Viruses in Older Inpatients: a Cohort Study
- ClinicalTrials.gov ID
- NCT07813481
- Acronym / sponsor ID
- ELREVI / APHP250510
- Conditions
- Influenza Viruses, Respiratory Syncytial Virus (RSV), Severe Acute Respiratory Syndrome Coronavirus 2, Human Metapneumovirus (hMPV), Parainfluenza Virus (PIV), Adenovirus
- Keywords
- hMPV, RSV, PIV, SarsCov2, respiratory viruses, older adults, prognosis, morbidity
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Study start
- Oct 2026 (estimated)
- Primary completion
- Apr 2030 (estimated)
- Study completion
- Oct 2030 (estimated)
- First posted
- 10 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In addition to SarsCov2, the main viral respiratory risks are associated with influenza viruses, respiratory syncytial virus (RSV), human metapneumovirus (hMPV) parainfluenza virus (PIV), adenovirus, rhinovirus, coronavirus and others. HMPV is a respiratory virus discovered in 2001. Like RSV, it appears to be a threat in terms of morbidity and mortality in susceptible populations.
Overall, viral infections can cause significant functional decline in older patients, with 67% and 25% reported to be at least temporarily housebound or bedridden, respectively. Respiratory viral infections prevent older patients from functioning and performing their daily tasks. They therefore have a significant impact on the older patients and their families. In addition, respiratory viruses are key factors in the exacerbation of chronic diseases.
The aims of this study are to provide a better understanding of the role of hMPV compared to common respiratory viruses on morbimortality, risk of dependency, quality of life alteration in older inpatients.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Older patients with respiratory viral infection | – | Other: Respiratory viral infectionPatients aged 65 years or older hospitalized in acute medicine or geriatric wards with an acute respiratory infection and a positive nasopharyngeal PCR test for a respiratory viral pathogen. |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- Patients aged >65 years with a diagnosis of acute respiratory infection and hospitalized in acute/geriatric wards
Key inclusion criteria (5 listed)
- Patient aged 65 years or older
- Positive PCR from a nasopharyngeal swab for a respiratory viral pathogen as listed: Influenza A and B, SarsCov2, RSV, hMPV, Rhinovirus/Enterovirus, Adenovirus, Coronavirus (229E, HKU1, NL63, OC43), Parainfluenza Virus 1, 2, 3, 4.
- Hospitalized in an Acute Medicine/Geriatrics Unit
- Written informed consent from patient or his/her representative, with trusted support person, a family member or, failing that, a close friend if the person is physically unable to give his or her written consent. Patients under legal protection (guardianship, curatorship, family authorisation or future protection mandate) may be included with the consent of the legally authorised person.
- Affiliated to a social security scheme
Key exclusion criteria (2 listed)
- Refusal to participate
- Patient deprived of liberty by a judicial or administrative decision
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Respiratory viral infectionRespiratory viral infection identified by a positive nasopharyngeal PCR test. The prognostic role of human metapneumovirus (hMPV) infection will be compared with that of other common respiratory viral infections in older hospitalized patients. | Other | Older patients with respiratory viral infection |
Primary outcome
Proportion of participants with death and/or organ decompensation at Day 180
Time frame: From baseline Day 0 to Day 180
Proportion of participants who died and/or experienced at least one major comorbidity decompensation (cardiac, renal, or respiratory) by Day 180.
10 secondary outcomes
Proportion of participants who died
Time frame: From baseline Day 0 to Day 30, Day 180, Day 365
Proportion of participants with major organ decompensation
Time frame: From baseline Day 0 to Day 30, Day 180, Day 365
Proportion of participants with unplanned hospital readmission
Time frame: From baseline Day 0 to Day 30, Day 180, Day 365
Proportion of participants developing a lower respiratory tract infection
Time frame: From baseline Day 0 to Day 30
Change from baseline in functional dependency assessed by ADL and/or iADL scores
Time frame: Baseline Day 0, Day 30, Day 180, Day 365
Change from baseline in sarcopenia risk assessed by SARC-F score
Time frame: Baseline Day 0, Day 30, Day 180, Day 365
Change from baseline in quality of life assessed by EQ-5D-3L
Time frame: Baseline Day 0, Day 30, Day 180, Day 365
Number and type of bacterial and viral co-infections
Time frame: Baseline Day 0 to D7
Change in respiratory viral load between Day 0 and Day 7
Time frame: From Day 0 to Day 7
Proportion of participants with death and/or major organ decompensation at Day 30
Time frame: From baseline Day 0 to Day 30
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Influenza Viruses
Not yet recruitingPhase 2/3
Evaluation of the Efficacy and Safety of 102D-6 in the Treatment of Acute Uncomplicated Influenza
Influenza, Human
RecruitingPhase 2
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
COVID 19, Influenza
Not yet recruiting
Family Physician Nudges for Influenza Vaccination Among Older Adults
Influenza Vaccination
Recruiting
Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections
COVID-19 Respiratory Infection, Influenza
RecruitingPhase 2
BPL-1357 Against H1N1 Influenza Virus Challenge
Influenza, Human
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Influenza Viruses and Respiratory Syncytial Virus (RSV), run by Assistance Publique - Hôpitaux de Paris.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 10 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Giovanna Mrs MELICA, MD, PhD (01 49 81 2455, giovanna.melica@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of participants with death and/or organ decompensation at Day 180 (time frame: From baseline Day 0 to Day 180). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2026.